Ladiratuzumab vedotin is an antibody-drug conjugate (ADC) targeting LIV-1 (IC50: 5.6 nM), composed of a humanized monoclonal antibody, MMAE, and a protease-cleavable linker. It drives immunogenic cell death (ICD) to elicit an immune response and can be used in breast cancer research.

LIV-1:5.6 nM

Ladiratuzumab vedotin induces endoplasmic reticulum stress in LIV‑1‑positive cells by activating ATF6 and promoting phosphorylation of IRE1 and eIF2α .Treatment of LIV‑1‑positive cells with ladiratuzumab vedotin results in the release of ATP and HMGB1 into the cell supernatant, exhibiting typical characteristics of immunogenic cell death [3].Ladiratuzumab vedotin shows significant cytotoxicity against MCF‑7 cells in the concentration range of 0–100 ng/mL [4].After treatment with 1 μg/mL ladiratuzumab vedotin for 24 hours, the drug is internalized and transported to lysosomes, while disrupting the microtubule structure in MCF‑7 cells [4].

Ladiratuzumab vedotin administered intraperitoneally at 3 mg/kg every 4 days induces tumor regression in the MCF-7 breast cancer xenograft model [4].

Human

Monoclonal, ADC

MMAE